Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | MMP12 | P39900 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | MMP14 | P50281 | 1/20 | 0.33 |
| ▸ | MMP16 | P51512 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3884280 | 1.00 | TRPV4 (0.35) | TRPV4ALDH1A1HSD11B1HSD17B10TDP1 | |
| SCHEMBL1501176 | 0.84 | ALDH1A1 (0.34) | TRPV4ALDH1A1HSD11B1HSD17B10TDP1 | |
| SCHEMBL780316 | 0.82 | MYC (0.39) | HSD11B1HTR2AHTR2CKCNH2MMP1 | |
| SCHEMBL5597793 | 0.81 | SMN1; SMN2 (0.42) | TRPV4ALDH1A1HSD17B10TDP1MMP1 | |
| SCHEMBL5097801 | 0.79 | CA12 (0.34) | TRPV4ALDH1A1HSD17B10TDP1MMP1 | |
| SCHEMBL1415493 | 0.79 | L3MBTL1 (0.46) | TRPV4ALDH1A1HSD11B1HSD17B10TDP1 | |
| SCHEMBL3951965 | 0.77 | TRPV4 (0.37) | TRPV4ALDH1A1HSD17B10TDP1 | |
| SCHEMBL10645229 | 0.77 | ALDH1A1 (0.38) | TRPV4ALDH1A1HSD11B1HSD17B10TDP1 | |
| SCHEMBL1415486 | 0.76 | TRPV4 (0.40) | TRPV4ALDH1A1HSD11B1HSD17B10TDP1 | |
| SCHEMBL1488023 | 0.76 | RECQL (0.41) | ALDH1A1TDP1L3MBTL1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150175570-A1 | BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-25 | — | — | US | disclosed |
| EP-2203426-B9 | BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2013-02-13 | — | — | EP | disclosed |
| EP-2203426-B1 | BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2011-08-31 | — | — | EP | disclosed |
| US-20100210664-A1 | BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2010-08-19 | — | — | US | disclosed |
| EP-2203426-A1 | BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009056600-A1 | BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175570-A1 | BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | DRD3, SLC6A3, DRD2 | TRPV4 817/4885ALDH1A1 1299/4885HSD11B1 495/4885 |
| US-20100210664-A1 | BENZENESULFONAMIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | DRD3, SLC6A3, DRD2 | TRPV4 817/4885ALDH1A1 1299/4885HSD11B1 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.